Plain-English translation of NCT05305859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications — venetoclax, chidamide, and azacitidine — to treat a serious blood cancer called acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. Early results in a small number of patients were encouraging, showing that the medication combination was well tolerated and helped patients go into remission. This study will enroll 30 patients to see if this new three-drug approach is safe and effective for more people.
Adults with AML that returns or resists standard treatment have very poor outcomes and limited options. While two of these medications together (venetoclax and azacitidine) help about 30-40% of patients, the benefit typically lasts only about one year. Adding the third medication may help patients respond better and stay in remission longer.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive the three-drug treatment combination in 28-day cycles, with each cycle lasting at least 2 weeks of active medication dosing. You will take chidamide twice a week for 2 weeks, venetoclax daily for 2 weeks, and azacitidine daily for the first 7 days of each cycle. You will need to complete at least 2 cycles of treatment and will have regular blood tests and check-ups to monitor how you're responding and watch for side effects. The study is taking place at a hospital in China and will involve approximately 30 patients total.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Collaborators
Fujian Provincial Hospital, Fujian Cancer Hospital
Enrollment target
~30 participants
Started
January 2022
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bing Xu, M.D.
The First Affiliated Hospital of Xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.